ABSTRACT
Objective To provide references for clinical rational utilization of TCM injections for activating blood circulation to dissipate blood stasis. Methods Retrospective analysis was used to sort and analyze in terms of species, consumption sum, DDDs and DDDc of TCM injections for activating blood circulation to dissipate blood stasis in Lanzhou Second People's Hospital (here in after referred to as our hospital) during 2014‐2016. Results The consumption sum of TCM injections for activating blood circulation to dissipate blood stasis was relatively high in the consumption sum of TCM injections (over 30％), and the type of TCM injections for activating blood circulation to dissipate blood stasis kept stable (up to 9‐11) in our hospital during 2014‐2016. The annual growth rate of consumption sum in 2016 (-5.42％) was significantly lower than it in 2015 (11.63％). Danshen Injection featured high selectivity and economical in the clinical application (DDDs: 12 600 in 2015, 6600 in 2016; DDDc: 32.70 in 2015, 28.46 in 2016; sorting ratio: 5.00 in 2015, 3.00 in 2016). Conclusion The clinical application of TCM injections for activating blood circulation to dissipate blood stasis tends to be rational in our hospital. Danshen Injection features high selectivity and economical in the clinical application. Danhong Injection features high selectivity but the poor economical.
ABSTRACT
Objective To understand the application situation of Chinese patent medicine during 2014-2017 in Changshu No.1 People's Hospital (hereinafter referred to as "our hospital"); To provide references for clinical rational medication. Metheds The data of Chinese patent medicine used in our hospital in 2014-2017 were retrieved from our hospital HIS. The consumption sum, annual growth rate, DDDs, sorting ratio and DDDc of Chinese patent medicine were analyzed statistically according to the defined daily dose recommended by WHO. Results During 2014-2017, the consumption sums of Chinese patent medicine were 49.155 2 million yuan, 51.352 7 million yuan, 49.463 7 million yuan and 45.650 4 million yuan, respectively. The consumption sums of Chinese patent medicine of 2015, 2016 and 2017 increased by 4.47％, -3.68％ and-7.71％, respectively. The proportions of consumption sum of Chinese patent medicine in all medicines were 13.63％ in 2014, 13.36％ in 2015, 12.83％ in 2016 and 12.44％ in 2017. Of all the dosage forms of Chinese patent medicine, capsule (32.67％), injection (25.21％) and tablet (14.71％) ranked the top 3 on the list of consumption sum. Of all the single kinds of Chinese patent medicine, blood rationing medicine, heat-clearing medicine and tonifying medicine ranked the top 3 on the list of consumption sum. The blood rationing medicine, gynecologic medicine and tonifying medicine ranked the top 3 on the list of DDDs. The first varieties of single item of consumption sum were salvianolate injection, Pudilan Xiaoyan Oral Liquid and Xueshuantong Injection (freeze-dried). The first varieties of single items of DDDs were Yinxing Tongzhi Dispersible Tablet and Pudilan Xiaoyan Oral Liquid. Conclusion The use of Chinese patent medicine in our hospital is becoming more reasonable, and the role and advantages in the prevention and control of diseases are constantly emerging. However, there are still problems about irrational medication, which need to be further strengthened.
ABSTRACT
OBJECTIVE: To investigate the rationality and trend of utilization of proton pump inhibitors (PPIs) in six areas in China in 2011-2013. METHODS: The utilization of PPIs in Beijing, Chengdu, Guangzhou, Shanghai, Tianjin, and Hangzhou during the period of 2011-2013 were analyzed statistically in respect of consumption sum, DDDs, AARG, DDC, drug interactions, and medical insurance categary. RESULTS: Both the consumption sum and DDDs of PPIs increased quickly in the recent three years. The amount of omeprazole was the greatest and increased steadily. The amounts of rabeprazole and lansoprazole also increased rapidly especially for the domestic products. Medical insurance categary had no obvious effect on clinical choice. PPIs became more cheaper for patients. Rabeprazole and pantoprazole were preferred when PPIs were combined with other drugs, especially in the hospitals which had clinical pharmacist working in the department of gastroenterology or cardiology. CONCLUSION: The use of PPIs tends to be more rational, in which clinical pharmacists play a very important role.